Source: Annual Congress 2013 –Disease control and quality of life in airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Okada, Y. Kono, S. Soeda, H. Hara, K. Araki, M. To, Y. To (Tokyo, Koshigaya, Japan). LATE-BREAKING ABSTRACT: A useful physiological marker for evaluating the effect of indacaterol in COPD patients.. Eur Respir J 2013; 42: Suppl. 57, 807

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Tiotropium efficacy and exacerbation risk in patients with different blood eosinophil levels Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 LATE-BREAKING ABSTRACT: An algorithm for the identification of clinical COPD phenotypes in daily practice Source: International Congress 2016 – COPD diagnosis and management Year: 2016 LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Longitudinal changes in COPD patients in primary care Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 LATE-BREAKING ABSTRACT: Usefulness of daily physical activity for monitoring therapeutic response in COPD Source: Annual Congress 2013 –New physiologic boundaries Year: 2013 Reduction in clinically important deterioration in COPD with aclidinium/formoterol Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Change in the COPD assessment test (CAT) score as predictor of short-term evolution of patients admitted for an exacerbation of COPD Source: International Congress 2014 – COPD: points to ponder Year: 2014 Indacaterol/glycopyrronium (IND/GLY) is superior to salmeterol/fluticasone (SFC) in improving the health status of patients with moderate-to-very severe COPD: Results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LATE-BREAKING ABSTRACT: The prevalence of night and morning symptoms in primary care COPD patients: How do they relate to COPD health status and disease severity? An UNLOCK study Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Short-term evaluation of a remote patient support program in patients with COPD and frequent exacerbations. ESOPO study Source: International Congress 2015 – Asthma and COPD: overlap and exacerbations Year: 2015 LATE-BREAKING ABSTRACT: Antioxidant supplementation in chronic obstructive pulmonary disease (COPD): A relevant way to optimize pulmonary rehabilitation effects Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016 LATE-BREAKING ABSTRACT: The effect of beta2-agonist on lung clearance index in COPD patients Source: International Congress 2015 – Lung function: new findings and approaches Year: 2015 LATE-BREAKING ABSTRACT: Cost-effectiveness of the LABA/LAMA dual bronchodilator QVA149 in a Swedish setting Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Modelling the long-term effects of an active case finding programme for undiagnosed COPD Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 LATE-BREAKING ABSTRACT: Validation of the DECAF score to predict hospital mortality in exacerbations of COPD Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 LATE-BREAKING ABSTRACT: Intra-day symptoms fluctuations: STORICO, observational study on the characterization of 24-hour symptoms in COPD patients Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Impact of lung function impairment and exacerbation history on COPD patient-reported utility Source: International Congress 2014 – COPD markers Year: 2014